

Agreement Form For Initiating Pr MINT-EMTRICITABINE/ TENOFVIR for Pre-exposure Prophylaxis (PrEP) in adults at high risk of HIV-1 infection

Individual Label

Instructions: Review form with an HIV-negative person who is about to start or is taking MINT-EMTRICITABINE/TENOFVIR for a PrEP indication at each visit. File form in the person's medical record.

MINT-EMTRICITABINE/TENOFVIR is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. The following factors may help to identify individuals at high risk:

- Has partner(s) known to be HIV-1 infected, or
- Engages in sexual activity within a high prevalence area or social network and one or more of the following:
 - Inconsistent or no condom use
 - Diagnosis of sexually transmitted infections
 - Exchange of sex for commodities (such as money, shelter, food, or drugs)
 - Use of illicit drugs, alcohol dependence
 - Incarceration
 - Partner(s) of unknown HIV-1 status with any of the factors listed above

Healthcare Provider Agreement

By signing below, I signify my understanding of the risks and benefits of MINT-EMTRICITABINE/TENOFVIR for a PrEP indication and my obligation as a prescriber to educate the HIV-negative person about these risks, counsel the person on risk reduction, monitor the person appropriately, and report adverse events.

Specifically, I attest to having done the following:

- Confirmed the negative HIV-1 status of this person prior to starting MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Read the Product Monograph, including BOXED WARNINGS
- Discussed with the HIV-negative person the known safety risks with use of MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Reviewed the importance of adherence with a comprehensive prevention strategy, including practicing safer sex
- Discussed the importance of regular HIV-1 testing (at least every 3 months) while taking MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Reviewed the MINT-EMTRICITABINE/TENOFVIR Uninfected Individual Safety Brochure with the HIV-negative person at high risk prior to prescribing MINT-EMTRICITABINE/TENOFVIR for a PrEP indication
- Completed the items on the Checklist for Prescribers: Initiation of MINT-EMTRICITABINE/TENOFVIR for Pre-Exposure Prophylaxis (PrEP)

HIV-Negative Person Agreement

By signing below, I acknowledge that I have talked with my healthcare provider about the risks and benefits of MINT-EMTRICITABINE/TENOFOVIR to reduce the risk of getting HIV-1 infection, and I understand them clearly.

- My healthcare provider talked with me about the importance of follow-up HIV-1 testing, and I agree to have repeat HIV-1 screening tests (at least every 3 months) as scheduled by my healthcare provider
- My healthcare provider talked with me about the safety risks involved with using MINT-EMTRICITABINE/TENOFOVIR to reduce the risk of getting HIV-1 infection
- My healthcare provider talked with me about a complete prevention strategy and always practicing safer sex by using condoms correctly
- I will talk with my healthcare provider if I have any questions
- I have read the MINT-EMTRICITABINE/TENOFOVIR uninfected individual safety brochure

Please consult the Consumer Information section of the Product Monograph for information on warnings, precautions and side effects.

Healthcare Provider's Signature

Date

HIV-Negative Person's Signature

Date

MINT-EMTRICITABINE/TENOFOVIR is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

Consult the product monograph at www.mintpharmaceuticals.com for contraindication, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-877-398-9696.